The efficacy of anti-Aβoligomer antibody to the toxicity of Aβto neuronal cells

抗Aβ寡聚体抗体对抗Aβ对神经元细胞毒性的功效

• 批准号: 21591524
• 负责人: HAYASHI Yoshihito
• 金额: $ 3万
• 依托单位: University of Miyazaki
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21591524/
• 关键词: アルツハイマー型認知症; βアミロイド; オリゴマー; 神経細胞保護

The most popular type of dementia is Alzheimer's disease(AD). The cause of AD is thought that amyloid beta protein(Aβ) cleaved from amyloid precursor protein(APP) which is expressing on the neuronal cell membranes has neurotoxicity and induce neuronal cell death. Recently some researchers found the soluble oligomer form had toxicity to the synapses and induce cognitive decline. We thought that anti-oligomer antibody has neuroprotective effect. We investigated the mechanisms of neuroprotective effect of anti-oligomer antibody against neuronal cells from Aβtoxicity. We investigated whether or not anti-oligomer antibody reduce the amount of free radical formation when Aβaggregate themselves. The amount of free radical formation was reduced compared with control solution. The viability of PC12 cells was higher when culture medium was added anti-oligomer antibody with Aβ. We found some changes of amount of NMDA receptor in PC12 when added Aβto culture medium with anti-oligomer antibody. We did not confirm whether the effect of anti-oligomer antibody against NMDA receptor was direct or indirect effect. We thought that there are some relations between two properties.

最常见的痴呆类型是阿尔茨海默病（AD）。AD的病因被认为是从淀粉样蛋白前体蛋白（APP）中分离出来的淀粉样蛋白（Aβ）在神经元细胞膜上表达，具有神经毒性并诱导神经元细胞死亡。近年来，一些研究人员发现可溶性低聚物形式对突触具有毒性，可引起认知能力下降。我们认为抗低聚物抗体具有神经保护作用。我们研究了抗寡聚物抗体对a β毒性神经元细胞的神经保护作用机制。我们研究了抗低聚物抗体是否减少了a β聚集时自由基的形成量。与对照液相比，自由基生成量减少。在培养液中加入Aβ抗低聚物抗体后，PC12细胞活力提高。我们发现在含有抗低聚物抗体的培养基中加入a β后，PC12中NMDA受体的数量发生了一些变化。抗寡聚物抗体对NMDA受体的作用是直接作用还是间接作用，我们尚未证实。我们认为两个性质之间有一些关系。

项目成果

An open label study to ascertain the effect of a traditional Japanese medicine, yokukansan, short-term treatment on the BPSD in patients with AD

一项开放标签研究，旨在确定日本传统药物 yokukansan 的短期治疗对 AD 患者 BPSD 的影响

• 发表时间: 2011
• 作者: Hayashi Y;Ishida Y;Okahara K;Mitsuyama Y
• 通讯作者: Mitsuyama Y

アルツハイマー型認知症の周辺症状(BPSD)に対する抑肝散の効果-日常診療下における検討:入院患者における部分集団解析-

抑肝散对阿尔茨海默病（BPSD）周围症状的影响 - 日常临床实践检查：住院患者的亚组分析 -

• 发表时间: 2010
• 期刊: Geriatric Medicine(老年医学)
• 作者: 林要人;石田康;井上輝彦;宇田川充隆;竹内康三;木上幸一郎;二宮嘉正;河野次郎;鮫島哲郎;川原岳;後藤勇;首藤謙二;倉山茂樹;中村純五;岡原一徳;三山吉夫
• 通讯作者: 三山吉夫

A multicenter open label study to investigate the effect of a traditional Japanese medicine, yokukansan, on the behavioral and psychological symptoms of dementia in patients with Alzheimer's disease

一项多中心开放标签研究，旨在调查日本传统药物“抑肝散”对阿尔茨海默病患者痴呆行为和心理症状的影响

• 发表时间: 2009
• 作者: Yoshihito Hayashi;Y Mitsuyama;Y Ishida
• 通讯作者: Y Ishida

認知症患者の行動・心理症状(BPSD)に対する抑肝散長期投与の安産性および有効性の検討

检查长期服用 Yokukansan 对痴呆症患者行为和心理症状 (BPSD) 的安全给药和有效性

• 发表时间: 2012
• 期刊: Dementia Japan
• 作者: 岡原一徳;石田康;林要人;土屋利紀
• 通讯作者: 土屋利紀

Analgesic effect of milnacipran is associated with c-Fos expression in the anterior cingulate cortex in the rat neuropathic pain model

• DOI: 10.1016/j.neures.2009.04.010
• 发表时间: 2009-08-01
• 期刊: NEUROSCIENCE RESEARCH
• 影响因子: 2.9
• 作者: Takeda, Ryuichiro;Watanabe, Yuko;Ishida, Yasushi
• 通讯作者: Ishida, Yasushi